Patents by Inventor Donald Treacy
Donald Treacy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10532385Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: GrantFiled: June 29, 2017Date of Patent: January 14, 2020Assignee: DisposeRx, Inc.Inventors: Marcus Schestopol, Donald Treacy, Edward M. Rudnic, Beth A. Burnside, John W. Holaday
-
Publication number: 20190358687Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: ApplicationFiled: August 9, 2019Publication date: November 28, 2019Inventors: Marcus Schestopol, Donald Treacy, Edward M. Rudnic, Beth A. Burnside, John W. Holaday
-
Publication number: 20180001357Abstract: Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Applicant: DisposeRx, Inc.Inventors: MARCUS SCHESTOPOL, DONALD TREACY, EDWARD M. RUDNIC, BETH A. BURNSIDE, JOHN W. HOLADAY
-
Patent number: 9125803Abstract: Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.Type: GrantFiled: December 22, 2006Date of Patent: September 8, 2015Assignee: Shionogi Inc.Inventors: Henry H. Flanner, Donald Treacy, Sanna Tolle-Sander, Scott Ibrahim, Marcus Schestopol, Beth A. Burnside
-
Patent number: 8778924Abstract: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 2.0:1; and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1.Type: GrantFiled: December 4, 2006Date of Patent: July 15, 2014Assignee: Shionogi Inc.Inventors: Henry H. Flanner, Sanna Tolle-Sander, Donald Treacy, Beth A. Burnside, Susan P. Clausen
-
Publication number: 20140183070Abstract: A device for the neutralization and disposal of unused medicaments, such as drugs or medications. The device generally comprises a means of storing disposal device material, which can render medicaments unusable, and a means of exposing the disposal device material to the medicaments when they are no longer in use. The device may be a medicament container comprising a reservoir to store the disposal device material, and a means to expose the disposal device material to the medicaments. Alternatively, the device may be a medicament closure or lid for use with a medicament container, in which the closure comprises a reservoir for storing the disposal device material and a means to expose the disposal device material to the medicaments.Type: ApplicationFiled: August 2, 2013Publication date: July 3, 2014Applicant: QRxPharma Ltd.Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Donald Treacy, Marcus Schestopol, Kristin Benokraitis, Ed Browka, Jessie Delgado, David Foshee
-
Publication number: 20140187842Abstract: Device for the neutralization and disposal of unused human or animal pharmaceutical medicament. The device comprises a disposal device material that contains one or more disposal device agents. The disposal device material may also contain additional components to promote mixing, or neutralization of the active agent of the medicament. The disposal device material can be in the form of pellets, beads, beadlets, granules, or the like, and can be incorporated into a disposal device reservoir. The disposal device can be dispensed with a medicament, and the device can be used when the patient has finished using the medicament and there is material left over for disposal.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicant: QRxPharma Ltd.Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Marcus Schestopol, Donald Treacy, Michael Vachon, Sean Higgins, Gary W. Pace
-
Patent number: 8357394Abstract: Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.Type: GrantFiled: December 8, 2006Date of Patent: January 22, 2013Assignee: Shionogi Inc.Inventors: Henry H. Flanner, Robert J. Guttendorf, Susan P. Clausen, Donald Treacy, Beth A. Burnside
-
Patent number: 8299052Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.Type: GrantFiled: May 7, 2007Date of Patent: October 30, 2012Assignee: Shionogi Inc.Inventors: Henry H. Flanner, Robert Guttendorf, Donald Treacy, Susan P. Clausen, Beth A. Burnside
-
Publication number: 20100120896Abstract: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least two different antibiotics, wherein one of the at least two different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics and wherein one of the at least two different antibiotics is selected from the group consisting of Elongation Factor G (EF-G) Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics and Elongation Factor G (EF-G) Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhibitor, preferably a LexA protease cleavage inhibitor.Type: ApplicationFiled: July 1, 2009Publication date: May 13, 2010Inventors: Sanna Sander, Henry H. Flanner, Beth A. Burnside, Donald Treacy, Edward M. Rudnic
-
Publication number: 20100016333Abstract: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least three different antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics or Phenazine antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of Dihydropteroate Synthase Inhibiting antibiotics, and wherein one of the at least three different antibiotics is selected from the group consisting of Dihydrofolate Reductase Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics, Dihydropteroate Synthase Inhibiting antibiotics, and Dihydrofolate Reductase Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhibType: ApplicationFiled: August 7, 2007Publication date: January 21, 2010Inventors: Henry H. Flanner, Donald Treacy, Sanna Tolle-Sander, Beth A. Burnside, Edward M. Rudnic
-
Publication number: 20080139526Abstract: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein the product exhibits a mean in-vitro dissolution profile within a defined range characterized as follows: 1) the percent dissolved at 0.25 hours is between 25 and 55 percent; 2) the percent dissolved at 0.5 hours is between 30 and 60 percent; 3) the percent dissolved at 1 hour is between 50 and 85 percent; 4) the percent dissolved at 1.5 hours is between 70 and 95 percent; and 5) the percent dissolved at 2 hours is at least 85 percent.Type: ApplicationFiled: December 6, 2006Publication date: June 12, 2008Inventors: Donald Treacy, Alan R. Potts, Henry H. Flanner, Beth A. Burnside
-
Publication number: 20080132478Abstract: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 2.0:1; and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1.Type: ApplicationFiled: December 4, 2006Publication date: June 5, 2008Inventors: Henry H. Flanner, Sanna Tolle-Sander, Donald Treacy, Beth A. Burnside, Susan P. Clausen
-
Publication number: 20080050430Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.Type: ApplicationFiled: May 7, 2007Publication date: February 28, 2008Inventors: Henry Flanner, Robert Guttendorf, Donald Treacy, Susan Clausen, Beth Burnside
-
Publication number: 20070154547Abstract: Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.Type: ApplicationFiled: December 22, 2006Publication date: July 5, 2007Inventors: Henry H. Flanner, Donald Treacy, Sanna Tolle-Sander, Scott Ibrahim, Marcus Schestopol, Beth A. Burnside
-
Publication number: 20070134327Abstract: Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.Type: ApplicationFiled: December 8, 2006Publication date: June 14, 2007Inventors: Henry Flanner, Robert Guttendorf, Susan Clausen, Donald Treacy, Beth Burnside
-
Publication number: 20060193908Abstract: An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition.Type: ApplicationFiled: November 4, 2005Publication date: August 31, 2006Inventors: Beth Burnside, Colin Rowlings, Sandra Wassink, Donald Treacy, John Koleng
-
Publication number: 20060110455Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: November 14, 2005Publication date: May 25, 2006Inventors: Edward Rudnic, James Isbister, Donald Treacy, Sandra Wassink
-
Publication number: 20060003005Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.Type: ApplicationFiled: July 1, 2005Publication date: January 5, 2006Inventors: Bruce Cao, Sandra Wassink, Donald Treacy, Beth Burnside, Colin Rowlings, John Bonck
-
Publication number: 20050238714Abstract: An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.Type: ApplicationFiled: May 6, 2005Publication date: October 27, 2005Inventors: Edward Rudnic, James Isbister, Donald Treacy, Sandra Wassink